Find an expert

Professor Elizabeth (Lizzie) Coulson did her undergraduate Honours degree at the University of Melbourne, majoring in Genetics and Biochemistry. Her PhD (1997) in the Department of Pathology, University of Melbourne, with Professor Colin Masters, was on the normal function of the amyloid precursor protein of Alzheimer’s disease. Following a year at the ZMBH, University of Heidelberg, Germany, she pursued postdoctoral work studying neuronal cell death in neurodegeneration and development at the Walter and Eliza Hall Institute with Professor Perry Bartlett before being recruited in 2003 to the University of Queensland as a founding member of the Queensland Brain Institute. She was appointed Professor in 2015, joining the School of Biomedical Sciences and becoming Deputy Head of School in 2016/7 and 2019 and Head of School in 2020. She maintains a 20% Queensland Brain Institutes appointment and is a member of the Clem Jones Centre for Ageing Dementia Research.

Her Lab webpage is: Coulson Lab - Neurotrophin - School of Biomedical Sciences ...

Dr Gary Cowin is the Facility Fellow for the Queensland Node of the National Imaging Facility (NIF) as part of the National Collaborative Research Infrastructure Scheme (NCRIS), based at the Centre for Advanced Imaging, The University of Queensland.

Dr Cowin's research projects are:

• Ultrahigh field magnetic resonance microimaging
• Simultaneous dynamic MRI and PET imaging
• Multimodal MRI/PET/CT imaging
• Development of magnetic resonance techniques for non-invasive determination of liver steatosis and fibrosis
• Monitoring changing fat distribution in diabetes and exercise trials
• Spinal cord imaging research
• Prostate research
• Application of ultrahigh field MRI microimaging for tissue analysis
• Molecular imaging of novel contrast agents by MRI and PET
• MRI zebrafish brain atlas
• Lung imaging with hyperpolarized Helium in humans and animals
• Investigation of the effect of gradient non-linearity on image quality

David Craik (AO, FRS, FAA) is in the Centre for Chemistry and Drug Discovery at the Institute for Molecular Bioscience, The University of Queensland, Australia. He discovered the cyclotide family of circular proteins and has characterized the structures of many animal toxins including conotoxins from cone snail venoms. He heads a research team of 35 researchers whose current work focuses on applications of circular proteins, drugs in plants, toxins and NMR in drug design.

He is author of over 810 scientific papers, including 14 in Nature publications (Nature/Nature Communications/Nature Neuoroscience/Nature Structural Biology/Nature Chemical Biology/Nature Chemistry/Scientific Reports/Nature Protocols, 1 in Science, 12 in PNAS, 9 in JACS, 3 in Chemical Reviews, and 16 in Angewandte Chemie. He has been elected as a Fellow of the Royal Society and a Fellow of the Australian Academy of Science, appointed as an Officer (AO) of the Order of Australia and has received numerous awards for his research, including the Ralph F. Hirschmann Award from the American Chemical Society (2011), Ramaciotti Medal for Excellence in Biomedical Research (2014), GlaxoSmithKline Award for Research Excellence (2014), the Vincent du Vigneaud Award from the American Peptide Society (2015),the FAOBMB Award for Research Excellence (2015) and the Cathay Award from the Chinese Peptide Society (2018). He received the Australian Academy of Science David Craig Medal in 2023. He is an Honorary Professor of Jinan University, Guangzhou and has an Honorary Doctorate from Kalmar University in Sweden.

Biography

David Craik obtained his PhD in organic chemistry from La Trobe University in Melbourne, Australia and undertook postdoctoral studies at Florida State and Syracuse Universities before taking up a lectureship at the Victorian College of Pharmacy in 1983. He was appointed Professor of Medicinal Chemistry and Head of School in 1988. He moved to University of Queensland in 1995 to set up a new biomolecular NMR, held an Australian Research Council Laureate Fellow (2015-2020) and is currently a NHMRC Fellow, as well as Director of the Australian Research Council Centre of Excellence in Peptide and Protein Science.

Key Discoveries

David Craik has made discoveries of new classes of proteins, generated new knowledge on their structure and function, and used this information to design and chemically re-engineer new classes of protein-based drug leads and agricultural pest control agents. In particular, his major achievements are:

• the discovery of cyclotides, the largest known family of circular proteins. As well as a circular backbone, cyclotides contain a knotted arrangement of cross-linking disulfide bonds, making them remarkably stable. His discovery of these proteins was sparked in part from anecdotal reports of medicinal practices in Africa where women make a tea from the plant Oldenlandia affinis by boiling it in water and sipping it during labour to accelerate child birth. He determined the structure of the bioactive component of this medicinal tea and found that it had an unprecedented head-to-tail cyclic peptide backbone combined with a cystine knot.
• the first structural and functional characterizations of prototypic circular proteins in higher organisms - Professor Craik was one of the first to recognize that other families of ribosomally synthesized cyclic peptides exist. As examples from bacteria and animals emerged, Professor Craik was at the forefront of their structural characterization, reporting the first structures of theta-defensins from animals and the threaded lasso peptide microcin J25 from bacteria, as well as new examples of cyclic peptides from plants.
• the development of artificially cyclized peptide toxins as drug leads – he developed an orally active peptide that is 100 times more potent than the leading clinically used drug for neuropathic pain.

Research Training

Professor Craik has trained more than 70 PhD students. He was awarded UQ’s Research Supervision Excellence Award in 2007 on the basis of his mentoring and innovations in postgraduate training, including his “writing retreats” to mentor students and postdocs on science writing skills. He received the Institute for Molecular Bioscience Individual Leadership Award in 2019. He was awarded an honorary doctorate from Kalmar University, Sweden for his contributions to international student exchange programs, and is an Honorary Professor of Jinan University, Guangzhou.

Professional Activities

Professor Craik founded and chaired the 1st, 2nd and 3rd International Conferences on Circular Proteins (2009, 2012 and 2015) and was on the Scientific Program Committee for ISMAR 2021. He is on the Boards of six international journals, including Angewandte Chemie, ACS Chemical Biology, Chemical Biology and Drug Design, and ChemBioChem. He was on the Council of the American Peptide Society (2015-2021). He was the director two Brisbane-based biotech companies. He is on the Scientific Advisory Boards of James Cook University’s Centre for Biodiscovery and Molecular Development of Therapeutics (BMDT), the University of Wollongong’s Illawara Health and Medical Research Institute (IHMRI) and Enzytag. He conceived and supports two publicly accessible databases - Cybase on circular proteins (www.cybase.org.au), and conotoxins (www.conoserver.org).

Dr Emma Crawford is an occupational therapist and researcher whose work centres on promoting wellbeing for infants, children, families and communities. Emma's primary focus is on cross-cultural projects that link with community organisations to create social change and reduce the impacts of disadvantage by supporting health enhancing environments and activities in early life. At the centre of Emma's work is the United Nations Sustainable Development Goal 3 - ensuring healthy lives and promoting wellbeing across all ages. Currently, Emma is leading several projects:

1) The BABI Project (research): refugee and asylum seeker families' expereinces during the perinatal period (systematic review, qualitative focus group and interview research)

2) The Uni-Friends program (student delivered service and student placement) - a social-emotional helth promotion program that draws on cultural responsiveness (The Making Connecitons Framework) and community development principles in an Aboriginal and Torres Strait Islander Community Controlled School

3) LUCIE-NDC (research) - mothers' experiences of accessing Neuroprotective-Developmental Care in the first 12 months of their infants' lives

Emma has a strong interest in understanding human experiences, community-driven initiatives, and strengths-based, innovative, evidence based, complex approaches to wellbeing that consider individuals and systems She also carries out research regarding allied health student placements in culturally diverse settings including low-middle income countries and Indigenous contexts. She works as a Lecturer at the University of Queensland, Australia after having worked in a range of occupational therapy roles including with children with autism, with asylum seekers, with Indigenous Australians with chronic disease, and completing her PhD in Political Science and International Studies in 2015.

Scott manages the radiation oncology medical physics research portfolio at the Royal Brisbane and Women’s Hospital, including the supervision of higher degree research students. He joined the Cancer Care Services team in 2015, following a post-doctoral research fellowship and is registered as a qualified medical physics specialist with the Australasian College of Physical Scientists and Engineers in Medicine. He is the clinical lead of the Cancer Care Services program at the Herston Biofabrication Institute. His research interests include applications of 3D printing in oncology, the quantitative assessment of radiotherapy treatment quality and complexity, and radiation dosimetry.

Tegan is an Australian Research Council DECRA Fellow and Clinical Psychologist at the Australian National University, with an Honorary Senior Research Fellowship at the University of Queensland. Her research investigates how social relationships shape mental and physical health; work that is at the intersection of social, clinical and health psychology.

Up-to-date information about Dr Tegan Cruwys, including her recent work and best contact information, is available at her ANU webpage: https://researchers.anu.edu.au/researchers/cruwys-tl

Peter Csurhes is an immunologist with a strong research track record in multiple sclerosis (MS) research within UQ that has spanned 30 years.

Together with Emeritus Professor Michael Pender, Peter’s work in a number of preclinical research studies into the role that immunity to Epstein-Barr virus (EBV) plays in MS disease pathogenesis has translated to clinical trials testing of potentially ground-breaking new T cell immunotherapeutic treatments for progressive MS. Collaborative links between QIMR Berghofer, Royal Brisbane and Women’s Hospital and commercial partners have been established and clinical trials are ongoing.

After the retirement of Professor Pender, Peter has taken on a chief investigator role, and in 2023 gained successful NHMRC MRFF funding to continue research into the biology of the Epstein-Barr virus and the role it plays in the multiple sclerosis disease process.

Peter has also been involved in studying the role of reactivity to autoantigens in MS and in diseases of the peripheral nervous system including Guillain-Barre syndrome and CIDP.

For several years he worked on the immunology of potential malaria vaccine candidates and also worked part-time for 18 months on research into EBV-related cancers within the QIMR-Berghofer Medical Research Institute.

Dr Cuffe is a systems physiologist focused on understanding the complex changes to maternal physiology that occur during pregnancy and the impact of pregnancy dysfunction of programmed cardiovascular, metabolic and renal disease in offspring. Dr Cuffe has a particular focus on understanding the role of the placenta and its hormones in mediating both maternal and offspring disease. He is most recognised for his research investigating how maternal stress, thyroid dysfunction, hypoxia or altered nutrition affect placental development and program disease in the mother after pregnancy as well as her offspring. Dr Cuffe has an exceptional track record and is excited to take new honours and PhD students into his research laboratory.

Louise Cullen is a Pre-Eminent Staff Specialist in Emergency Medicine, a clinical trialist and outcomes researcher in acute diseases. She is enthusiastically involved in the translation of research by clinical redesign and innovation.

As an accomplished acute disease researcher, Prof Cullen has focused on the diagnosis and management of patients presenting with possible Acute Coronary Syndromes (ACS) in the Emergency Department (ED). She has been engaged in many international collaborations (including ASPECT and ADAPT studies) She has authored over 100 publications in peer-reviewed journals including The Lancet, focussed on strategies to improve efficiency, whilst maintaining safety for patients with possible ACS, syncope, heart failure, shortness of breath and atrial fibrillation.

More recently Prof Cullen has focussed on Health Services research and investigating methods to use medications and other resources in the ED wisely. She led the CREDIT trail, aimed at reducing unnecessary peripheral intravenous cannulation in the ED.

Professor Cullen’s mantra is that “you do not do research for research sake” and as such, clinical redesign and translational research is a key part of her endeavours.

Pre-Eminent Staff Specialist, Department of Emergency Medicine

Prof, Queensland University of Technology

A/Prof, University of Queensland

Royal Brisbane and Women’s Hospital

Brisbane, Queensland 4029, AUSTRALIA.

Tel: (+ 61 7) 3636 7901. Fax: (+ 61 7) 3636 1643.

Email: louise.cullen@health.qld.gov.au

Twitter: @louiseacullen

Qualifications: MBBS (Hon) FACEM PhD

Dr Carlie Cullen leads the Glial Neurobiology, Cognition and Behaviour Research Group at Mater Research and is an Honorary Senior Research Fellow at the Menzies Institute for Medical Research, University of Tasmania. Her research vision is to understand the neurobiological mechanisms that drive healthy brain function, and what happens when the system goes awry, to inform the development of sustained and effective treatments for neurodevelopmental, neurological, and neuropsychiatric disorders. More specifically, Carlie and her team are working to demonstrate the importance of myelin formation during brain development and ongoing adaptability of myelin content in shaping the way information is processed in the brain, and subsequently how this impacts behavioural actions throughout life. By uncovering how myelination and myelin plasticity influences brain function and behaviour, Carlie hopes to determine whether these processes could be targeted to treat the pathological symptoms of neurodevelopmental disorders, neuropsychiatric disease, and other neurological conditions.

Dr Cullen attained her PhD from The University of Queensland in 2014, under the supervision of Professor Karen Moritz, Associate Professor Nickolas Lavidis and Associate Professor Thomas Burne, where she used rodent models to demonstrate that chronic exposure to even a small amount of alcohol during gestation was associated with long-lasting anxiety-like behaviour in adult offspring. Carlie then joined the laboratory of Prof. Kaylene Young at the Menzies Institute for Medical Research, University of Tasmania where she developed a passion for understanding how glial cells influence healthy brain function, cognition and behaviour. In particular, her research focussed on understanding how cells of the oligodendrocyte lineage communicate with neurons; how this communication influences learning, memory and motor behaviour and whether this interaction could be targeted to promote brain repair in diseases like multiple sclerosis (MS).

Dr Katherine Cullerton is a Research Fellow in the School of Public Health. Katherine joined the School of Public Health in August 2018 after completing postdoctoral research at the MRC Epidemiology Unit at the University of Cambridge, UK where she investigated whether it’s ever acceptable for nutrition researchers to engage with the food industry and if it is, under what conditions. Her current research involves understanding the barriers to evidence informing public policy and how advocates can better influence policy in Australia with a particular emphasis on the effects of framing and public opinion.

Dr Cullerton is also the academic lead for external engagement for the School of Public Health.

My research focuses on Action and Attention in the human brain, examining neural activity underlying the preparation for voluntary movement and the recognition of others' actions

I am a Professor of Cognitive Neuroscience in the School of Psychology, University of Queensland. My major research interests include understanding the brain processes involved in attention and the preparation and readiness for voluntary action, the "mirror neuron" system and how we perceive and understand the actions of others.

Dr Andrew Dalley is a Postdoctoral Research Scientist within Dr Peter Simpson’s stream of the Molecular Pathology Research Programme at UQCCR. He is currently contributing to a clinician-lead research project that aims to validate diagnostic techniques for mediastinal lymph node dissemination of lung cancer.

Andrew is a practical molecular cell biologist with a strong focus towards clinically translatable research within the hospital setting. His academic experience spans adult and children’s burns research and adult cancer research. He has researched aberrant pharmacokinetics in burnt patients, post-burn hypertrophic scar development, cancer stem cell involvement in Head and Neck cancer development, and diagnostic techniques to define surgical borders for intra-oral cancer excision.

Andrew’s range of practical techniques includes: small molecule tissue sampling and analysis using microdialysis, HPLC and LC/MS; tissue imaging by fluorescence and confocal microscopy; cellular analysis by flow cytometry, live cell imaging, histology and real-time PCR; and patient sample molecular analysis by microarray and Next Generation Sequencing.

Andrew was recently Scientific Support Coordinator for the Cancer Programme at the Diamantina Institute, and prior to this he was Laboratory Studies Coordinator for Professor Camile Farah’s Oral Cancer Research Programme at UQCCR where he investigated the potential involvement of epithelial stem cells in pre-malignant oral dysplasia. Before this Andrew was part of the Burns Trauma & Critical Care Research Centre (BTCCRC) where he evaluated antibiotic distribution in extensively burned patients during surgery.

Formerly based in the UK, Andrew studied BSc Pharmacology and completed his PhD at The University of Sheffield under supervision from Professor Sheila MacNeil. Andrew’s PhD used 3-dimensional cultures to investigate regulation of normal and scar derived fibroblasts by dermal matrix and epithelial cells. Subsequently, he used in-vitro techniques to monitor the uptake of drugs across the gut mucosa and skin.

Andrew’s research interests include clinical diagnostic techniques, phenotypic and genotypic changes in pre-malignant dysplasia, extracellular matrix biology and its involvement in the pathophysiology of burn wound healing, epithelial / mesenchymal interaction across the basement membrane during the healing of cutaneous wounds, and drug distribution in critical patients.

Eminent Staff Specialist in Neonatology (Consultant Neonatologist) - Grantley Stable Neonatal Unit, Royal Brisbane & Women’s Hospital

Associate Professor of Neonatology - Department of Paediatrics and Child Health, University of Queensland

Mark Davies is a medical graduate of the University of Queensland (MB,BS 1985). He trained in Paediatrics at the Royal Children's Hospital (Brisbane), with time at the Worcester Royal Infirmary, Doncaster Royal Infirmary and the Royal Hospital for Sick Children (Glasgow) in the UK.

Mark sub-specialised in Neonatology training at the Royal Women's Hospital (Brisbane), the Rosie Maternity Hospital (Cambridge) and the Glasgow Royal Maternity Hospital. His advanced training was conducted under the supervision of the Neonatal-Perinatal Specialist Advisory Committee of the Royal Australasian College of Physicians (RACP) and he became a Fellow of the RACP in 1997. He completed a two year fellowship training programme in Neonatology and Neonatal Ultrasound at the Royal Women's Hospital (Melbourne) in January 1999.

In July 2000, Mark was appointed to the joint position of Staff Neonatologist at the Royal Women's Hospital, Brisbane and Senior Lecturer in Neonatology at the University of Queensland. He is now an Eminent Staff Specialist in Neonatology and an Associate Professor of Neonatology.

Mark Davies’ research focused on neonatal ventilation. He did his PhD studies on partial liquid ventilation. He supervises projects in neonatology and neonatal intensive care.

Mark prepares and maintains a number of Cochrane systematic reviews in neonatology and intensive care. From 2002 to 2006 he served on the Cochrane Collaboration Steering Group, and was Co-Chair of the steering group from 2005 to 2006. He was a Director of The Cochrane Collaboration Trading Company from 2013 to 2017.

My research concerns i) understanding causes and impacts of hearing impairment, particularly in the context of multimorbidity in older age, ii) prevention and treatment of hearing impairment, and iii) hearing service development and evaluation. My research involves epidemiological modelling with population data sets, clinical trials and hearing health policy. I have authored over130 publications in peer reviewed journals and books, and I frequently present invited and keynote addresses at international conferences. I have received the British Society of Audiology’s TS Littler prize for services to audiology and a prestigious US-UK Fulbright award.

I have been awarded 10 grants as principal investigator in the last 5 years totalling >AUD$14.5 million from competitive sources including the NHMRC, the NIHR, the Alzheimer’s Society UK, the European Commission, industry and charity funders. This funding includes an EU Horizon 2020 grant of €6.2 million (as joint PI for “Ears, Eyes and Mind: The “SENSE-Cog Project” to improve mental well-being for elderly Europeans with sensory impairment”), and two NHMRC Medical Research Future Fund awards ($1.2 million as CI for “SENSEcog aged care: Hearing and vision support to improve quality of life for people living with dementia in residential aged care”; AUD$1.3 million for "Home hearing and vision care to improve quality of life for people with dementia and carers"; and an AUD$0.9 million NHMRC targetted hearing research award (as CI for "Improving access to the hearing services program for people from culturally and linguistically diverse backgrounds"). I have strong links with hearing industry partners and have received research funding (total >AUD$500,000) from major hearing aid companies Starkey, Oticon, Phonak and the hearing industry research consortium. I have a position at the University of Manchester with on-going involvement (as CI and co-I) in projects funded by the NIHR, the ESRC, the Alzheimer’s Society and the RNID.

Associate Professor Paul Dawson is the Mater Research Head of Education, MRI-UQ Director of Higher Degree Research, and a Mater Foundation Principal Research Fellow. Paul leads the Neurodevelopmental Research Group at Mater, which is focussed on cerebral palsy in preterm infants, non-syndromic intellectual disability and autism.

Paul’s research group collaborates very closely with neonatologists, maternal fetal medicine specialists, obstetricians, bioinformaticians and biochemical pathologists at Mater to investigate clinical, biochemical and genetic markers that predict adverse neurodevelopmental outcomes. In particular, his research is focussed on the role of nutrient sulphate in brain development. Paul through his work has brought many collaborative groups together. Some of his notable collaborations are with the Queensland Brain Institute (QBI), Royal Brisbane and Women’s Hospital (RBWH), UQ Centre for Clinical Research (UQCCR), the University of Sydney and the Cerebral Palsy Alliance.

With over 80 research publications, Paul notes a career highlight as being one of the key investigators, and Autism Biobank member, in the Autism Cooperative Research Centre (CRC) which was awarded $31 million from the Australian government.

Paul is heavily involved in national and international peer review and is a strong advocate for health and medical research with executive roles (Past-President 2012, Chair Advisory Committee) for the Australian Society for Medical Research (ASMR).

‘My career in medical research happened for many reasons, including my interest and passion for understanding the genetics of disorders that impact on people’s health and well-being. In my early days, I was fortunate to work with a group of like-minded biomedical and clinician scientists which kicked off many discoveries in neurodevelopment, as well as the opportunity to develop and investigate pre-clinical models with the aim of implementing research outcomes to improve healthcare. Working at Mater provides a fantastic opportunity to investigate new approaches for reducing the risk of adverse neurodevelopmental outcomes in preterm infants. I look forward to the coming years when the benefits of our Mater-led research will be realised and proven around the globe. It’s a privilege to contribute to Australian health and medical research.’

I am an endorsed Clinical and Health Psychologist, and my main area of research interest is in optimising non-pharmacological treatment options for chronic pain. My program of research is primarily focused on implementing randomised controlled trials designed to evaluate the efficacy and mechanisms of cognitive-behavioural and mindfulness-based interventions for heterogeneous chronic pain conditions. My concurrent line of research aims to further our understanding of the experience of chronic pain via converging methodologies (including experimental pain paradigms and electroencephalogram), as well as advance our capacity to accurately assess its multidimensional nature. I have led the development, application, and evaluation of Mindfulness-Based Cognitive Therapy for chronic pain, and I disseminated this treatment approach for research and clinical use via my sole-authored book, published by Wiley in 2017. My US-based collaborators and I have a number of on-going NIH and foundation funded treatment trials underway at the University of Washington, Seattle. I am also an Affiliate Associate Professor at the University of Washington.

As of 2021, I was elected the inaugural Chairperson of the Australian SHAPE Futures EMCR Network, which is in development with the support of the Australian Academy of the Humanities and the Australian Academy of the Social Sciences. The purpose of the Network is to ensure SHAPE disciplines (Social Sciences, Humanities, and the Arts for People and Environment) thrive and excel in Australia, by fostering an inclusive and diverse community that supports, empowers and promotes early and mid-career researchers (EMCRs) in Australia, within and beyond academia.